Results 31 to 40 of about 423,899 (348)

High geographic prevalence of pulmonary artery hypertension: associations with ethnicity, drug use, and altitude

Pulmonary Circulation, 2020
While estimates of pulmonary arterial hypertension incidence and prevalence commonly range from 1–3/million and 15–25/million, respectively, clinical experience at our institution suggested much higher rates.
Jason Dubroff, Lana Melendres, Yan Lin, Daniel Raley Beene, Loren Ketai   +4 more
doaj   +1 more source

Clinical implications of partial anomalous pulmonary venous connection: a rare cause of severe pulmonary arterial hypertension

Pulmonary Circulation, 2020
Isolated partial anomalous pulmonary venous connection (PAPVC) is an uncommon congenital heart anomaly that is sporadically associated with pulmonary arterial hypertension in the adult population.
Alex Pizzini, Thomas Sonnweber, Renate Frank, Markus Theurl, Günter Weiss, Ivan Tancevski, Judith Löffler-Ragg   +6 more
doaj   +1 more source

Clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension

Journal of Cardiothoracic Surgery, 2021
Pulmonary arterial hypertension is a type of malignant pulmonary vascular disease, which is mainly caused by the increase of pulmonary vascular resistance due to the pathological changes of the pulmonary arteriole itself, which eventually leads to right ...
Jianying Deng
doaj   +1 more source

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.

New England Journal of Medicine, 2015
BACKGROUND Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce.
N. Galiè, J. Barberà, A. Frost, H. Ghofrani, M. Hoeper, V. McLaughlin, A. Peacock, G. Simonneau, J. Vachiéry, E. Grünig, R. Oudiz, A. Vonk-Noordegraaf, R. White, C. Blair, H. Gillies, K. L. Miller, Julia H N Harris, J. Langley, L. Rubin   +18 more
semanticscholar   +1 more source

Pulmonary arterial hypertension in pregnancy—a systematic review of outcomes in the modern era

Pulmonary Circulation, 2021
Pregnancy is hazardous with pulmonary arterial hypertension, but maternal mortality may have fallen in recent years. We sought to systematically evaluate pulmonary arterial hypertension and pregnancy-related outcomes in the last decade.
T. Low, N. Guron, R. Ducas, Kenichiro Yamamura, Pradeepkumar Charla, J. Granton, C. Silversides   +6 more
semanticscholar   +1 more source

Role of prostacyclin in pulmonary hypertension [PDF]

, 2014
Date of Acceptance: 11/12/2014 This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY-4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is ...
Ali FY, Butrous G, Chester AH, Geiger LE, Newsholme SJ, Nguyen H, Ruan CH, Smith WL, Whittaker N   +8 more
core   +3 more sources

Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review

Pulmonary Circulation, 2020
This systematic review of literature and online reports critically appraised incidence and prevalence estimates of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension to identify the most accurate estimates.
L. Leber, A. Beaudet, A. Muller
semanticscholar   +1 more source

Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve? [PDF]

, 2012
In the early 1990s, within three years of cloning of endothelin receptors, orally active endothelin receptor antagonists (ERAs) were tested in humans and the first clinical trial of ERA therapy in humans was published in 1995.
Barton, Matthias, Cleland, John G., Kohan, Donald E., Rubin, Lewis J., Theodorescu, Dan   +4 more
core   +1 more source

Incident pulmonary arterial hypertension associated with Bosutinib

Pulmonary Circulation, 2020
Pulmonary arterial hypertension is associated with tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia. Dasatinib is a known cause of drug-induced pulmonary arterial hypertension.
Shaun Yo, John Thenganatt, Jeffrey Lipton, John Granton   +3 more
doaj   +1 more source

Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management

European Respiratory Journal, 2019
Paediatric pulmonary arterial hypertension (PAH) shares common features of adult disease, but is associated with several additional disorders and challenges that require unique approaches.
E. Rosenzweig, S. Abman, I. Adatia, M. Beghetti, D. Bonnet, S. Haworth, D. Ivy, Rolf M.F. Berger   +7 more
semanticscholar   +1 more source